Tekla Life Sciences Stock Analysis
| HQL Stock | USD 16.96 0.10 0.59% |
Tekla Life Sciences holds a debt-to-equity ratio of 0.02. Tekla Life's financial risk is the risk to Tekla Life stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Tekla Life's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Tekla Life's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Tekla Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Tekla Life's stakeholders.
For most companies, including Tekla Life, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Tekla Life Sciences, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Tekla Life's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Tekla Life's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Tekla Life is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Tekla Life to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Tekla Life is said to be less leveraged. If creditors hold a majority of Tekla Life's assets, the Company is said to be highly leveraged.
Tekla Life Sciences is fairly valued with Real Value of 16.76 and Hype Value of 16.95. The main objective of Tekla Life stock analysis is to determine its intrinsic value, which is an estimate of what Tekla Life Sciences is worth, separate from its market price. There are two main types of Tekla Life's stock analysis: fundamental analysis and technical analysis.
The Tekla Life stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Tekla Stock Analysis Notes
About 29.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.98. Some equities with similar Price to Book (P/B) outperform the market in the long run. Tekla Life Sciences last dividend was issued on the 21st of November 2025. Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange. To learn more about Tekla Life Sciences call the company at 215 405 5700 or check out https://www.teklacap.com/hql.html.Tekla Life Sciences Investment Alerts
| Tekla Life Sciences has high likelihood to experience some financial distress in the next 2 years | |
| Tekla Life Sciences has a strong financial position based on the latest SEC filings | |
| On 12th of January 2026 Tekla Life paid $ 0.5 per share dividend to its current shareholders |
Tekla Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 500.51 M.Tekla Profitablity
The company has Net Profit Margin of 44.16 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of (3.47) %, which entails that for every $100 of revenue, it lost $3.47.Technical Drivers
As of the 1st of February, Tekla Life has the Risk Adjusted Performance of 0.0284, coefficient of variation of 3057.66, and Semi Deviation of 1.23. Tekla Life technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Tekla Life Sciences downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Tekla Life is priced more or less accurately, providing market reflects its prevalent price of 16.96 per share. Given that Tekla Life Sciences has jensen alpha of 0.0219, we advise you to double-check Tekla Life Sciences's current market performance to make sure the company can sustain itself at a future point.Tekla Life Sciences Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Tekla Life Sciences price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Tekla Life Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tekla Life insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tekla Life's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tekla Life insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tekla Life Outstanding Bonds
Tekla Life issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tekla Life Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tekla bonds can be classified according to their maturity, which is the date when Tekla Life Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Tekla Life Predictive Daily Indicators
Tekla Life intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tekla Life stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tekla Life Forecast Models
Tekla Life's time-series forecasting models are one of many Tekla Life's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tekla Life's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Tekla Life Bond Ratings
Tekla Life Sciences financial ratings play a critical role in determining how much Tekla Life have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Tekla Life's borrowing costs.| Piotroski F Score | 8 | Strong | View |
| Beneish M Score | (1.46) | Possible Manipulator | View |
Tekla Life Sciences Debt to Cash Allocation
Many companies such as Tekla Life, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Tekla Life Sciences has 1.73 M in debt with debt to equity (D/E) ratio of 0.02, which may show that the company is not taking advantage of profits from borrowing. Tekla Life Sciences has a current ratio of 1.31, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Tekla to invest in growth at high rates of return. Tekla Life Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Tekla Life's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Tekla Life, which in turn will lower the firm's financial flexibility.Tekla Life Corporate Bonds Issued
About Tekla Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tekla Life prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tekla shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tekla Life. By using and applying Tekla Stock analysis, traders can create a robust methodology for identifying Tekla entry and exit points for their positions.
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tekla Life to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. Market participants price Tekla higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tekla Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Tekla Life Sciences's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Life's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Tekla Life's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.